0. Advocacy Graphic

The Voice of Addiction Medicine

 Leading the movement to transform America's addiction treatment infrastructure and expand access to research-validated, results-based care

ASAM's Advocacy Principles

Advocacy Webpage Graphics Teach It
TEACH addiction medicine by expanding and strengthening our workforce and dispelling stigma
Advocacy Webpage Graphics Standardize It
STANDARDIZE the delivery of addiction medicine so that more patients receive high-quality, evidence-based care
0. Advocacy Webpage Graphics Cover It
COVER addiction medicine in a way that expands patient access to coordinated, comprehensive care
Advocacy Homepage HR 6 Graphic

It's time we treat addiction like other chronic diseases 


Advocacy Committees & Councils

ASAM's advocacy could not happen if not for the dedicated effort of our members.

0. Find a Policy Statement 1 - cropped

Public Policy Statements

Learn about ASAM's position on current policy issues.

Teamwork - smallest


ASAM is proud to work collaboratively with others to improve the lives of those living with addiction.
0. Advocacy Toolkits

Advocacy Toolkits

ASAM provides toolkits to help you advocate for public policies that advance addiction medicine and promote access to treatment

Legislative Tracker Graphic


ASAM Writes to FDA Regarding Need for More Medication Treatment Options for Patients with SUD

by | Mar 14, 2019
Foremost to the American Society of Addiction Medicine's (ASAM) mission is increasing access to and improving the quality of addiction treatment. Patients with substance use disorder (SUD), like all patients, should have available to them a robust and varied array of treatment options as no one treatment modality is appropriate or therapeutic for everyone.

The dearth of FDA-approved pharmacotherapies for the treatment of SUD prompted ASAM to write to the Food and Drug Administration (FDA) urging them to take into consideration the need for access to multiple treatment options for clinicians and their patients as they consider applications for new products to treat SUD. In the letter, ASAM emphasized that addiction is a complex condition and clinicians and their patients need access to multiple, nuanced treatment options to meet their unique needs and circumstances.

ASAM contends that access to multiple formulations and dosages expands the number of available effective and safe treatment options for SUD, and can help advance efforts to address the nation’s opioid overdose epidemic.

Read the letter here.